FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303904> ?p ?o ?g. }

• W4367303904 abstract "<h3>Objective:</h3> To estimate the prevalence of diagnosed and drug-treated pediatric essential tremor (ET) using two US healthcare claims databases. <h3>Background:</h3> Pediatric ET diagnosis may represent early-onset familial ET and is predominantly diagnosed through tertiary centers. The prevalence of pediatric ET is not well-understood. <h3>Design/Methods:</h3> A retrospective cohort study used the Merative™ MarketScan^® Research Databases (MarketScan^®) and Symphony Integrated Dataverse (IDV^®) (01/01/2016–12/31/2019) to estimate the number of US children (age <18 years) with ET. ET diagnosis was defined as ≥2 medical claims containing ICD-10-CM code G25.0 ≥1 and ≤365 days apart. Patients with drug-treated ET were defined as those with ≥180 days of observability following ET diagnosis who subsequently received any ET medication in 2019. Age-adjusted prevalence was used to estimate the number of US children with diagnosed and drug-treated ET. <h3>Results:</h3> Estimated age-adjusted numbers (95% CIs) of US children diagnosed with ET were 8362 (7626–9230) and 6281 (5923–6629) using MarketScan and IDV, respectively. Less than half of those diagnosed with ET received pharmacological treatment for ET. Specifically, the estimated proportions (95% CIs) of pediatric patients with drug-treated ET were 33.7% (28.7%–38.7%) and 38.1% (34.8%–41.3%), respectively. Estimated age-adjusted numbers (95% CIs) of pediatric patients with drug-treated ET were 2749 (2299–3238) and 2409 (2186–2655), respectively. Beta-blockers (57% and 55%, respectively) and anticonvulsants (36% and 44%, respectively) were the most common drug classes prescribed among treated patients. The most frequently prescribed beta-blocker and anticonvulsant were propranolol (55% and 52%, respectively) and topiramate (15% and 17%, respectively). <h3>Conclusions:</h3> To our knowledge, this is the first study to estimate the US prevalence of pediatric ET using large claims databases. Pediatric ET appears rare and, concordant with the literature, less common in children than in adults. Observed low drug-treatment rates are consistent with the slow, progressive nature of ET. <b>Disclosure:</b> Mr. Saad has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Saad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidinno Outcomes Research Inc.. Mr. Saad has received stock or an ownership interest from Jazz Pharmaceuticals. Dr. Markowitz has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Markowitz has stock in Jazz Pharmaceuticals, UCB Pharmaceuticals, J&J. Ms. Gibbs has received personal compensation for serving as an employee of Aetion, Inc. Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has received stock or an ownership interest from D F. Dr. Ni has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Ni has stock in Jazz Pharmaceuticals. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cala Health. Dr. Pahwa has received personal compensation in the range of $0-$499 for serving as a Consultant for Global Kinetics. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sunovion. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allevion. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroderm. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Photopharmics. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wren. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Biohaven. The institution of Dr. Pahwa has received research support from Boston Scientific. The institution of Dr. Pahwa has received research support from EIP. The institution of Dr. Pahwa has received research support from Global Kinetics. The institution of Dr. Pahwa has received research support from Amneal. The institution of Dr. Pahwa has received research support from Neuraly. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Pharma 2B. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theranexus. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Voyager. The institution of Dr. Pahwa has received research support from Neuroderm. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Lyons has a non-compensated relationship as a President with International Essential Tremor Foundation that is relevant to AAN interests or activities. Dr. Baladi has stock in Jazz Pharmaceuticals . Ms. Lin has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Lin has stock in Jazz Pharmaceuticals. Ms. Lin has received publishing royalties from a publication relating to health care." @default.
• W4367303904 created "2023-04-29" @default.
• W4367303904 creator A5009117789 @default.
• W4367303904 creator A5017270325 @default.
• W4367303904 creator A5021337348 @default.
• W4367303904 creator A5031722963 @default.
• W4367303904 creator A5039591054 @default.
• W4367303904 creator A5043771499 @default.
• W4367303904 creator A5053090781 @default.
• W4367303904 creator A5070605335 @default.
• W4367303904 creator A5078786005 @default.
• W4367303904 date "2023-04-25" @default.
• W4367303904 modified "2023-09-26" @default.
• W4367303904 title "Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases (S51.003)" @default.
• W4367303904 doi "https://doi.org/10.1212/wnl.0000000000202611" @default.
• W4367303904 hasPublicationYear "2023" @default.
• W4367303904 type Work @default.
• W4367303904 citedByCount "0" @default.
• W4367303904 crossrefType "proceedings-article" @default.
• W4367303904 hasAuthorship W4367303904A5009117789 @default.
• W4367303904 hasAuthorship W4367303904A5017270325 @default.
• W4367303904 hasAuthorship W4367303904A5021337348 @default.
• W4367303904 hasAuthorship W4367303904A5031722963 @default.
• W4367303904 hasAuthorship W4367303904A5039591054 @default.
• W4367303904 hasAuthorship W4367303904A5043771499 @default.
• W4367303904 hasAuthorship W4367303904A5053090781 @default.
• W4367303904 hasAuthorship W4367303904A5070605335 @default.
• W4367303904 hasAuthorship W4367303904A5078786005 @default.
• W4367303904 hasConcept C126322002 @default.
• W4367303904 hasConcept C160735492 @default.
• W4367303904 hasConcept C167135981 @default.
• W4367303904 hasConcept C17744445 @default.
• W4367303904 hasConcept C187212893 @default.
• W4367303904 hasConcept C199539241 @default.
• W4367303904 hasConcept C41008148 @default.
• W4367303904 hasConcept C71924100 @default.
• W4367303904 hasConcept C77088390 @default.
• W4367303904 hasConceptScore W4367303904C126322002 @default.
• W4367303904 hasConceptScore W4367303904C160735492 @default.
• W4367303904 hasConceptScore W4367303904C167135981 @default.
• W4367303904 hasConceptScore W4367303904C17744445 @default.
• W4367303904 hasConceptScore W4367303904C187212893 @default.
• W4367303904 hasConceptScore W4367303904C199539241 @default.
• W4367303904 hasConceptScore W4367303904C41008148 @default.
• W4367303904 hasConceptScore W4367303904C71924100 @default.
• W4367303904 hasConceptScore W4367303904C77088390 @default.
• W4367303904 hasLocation W43673039041 @default.
• W4367303904 hasOpenAccess W4367303904 @default.
• W4367303904 hasPrimaryLocation W43673039041 @default.
• W4367303904 hasRelatedWork W2105151527 @default.
• W4367303904 hasRelatedWork W2324013405 @default.
• W4367303904 hasRelatedWork W2748952813 @default.
• W4367303904 hasRelatedWork W2899084033 @default.
• W4367303904 hasRelatedWork W2951130915 @default.
• W4367303904 hasRelatedWork W3013145321 @default.
• W4367303904 hasRelatedWork W3014841908 @default.
• W4367303904 hasRelatedWork W3208090289 @default.
• W4367303904 hasRelatedWork W3210359220 @default.
• W4367303904 hasRelatedWork W4313574608 @default.
• W4367303904 isParatext "false" @default.
• W4367303904 isRetracted "false" @default.
• W4367303904 workType "article" @default.